NKGen Biotech to Present Posters at 17th Annual CTAD Conference

SANTA ANA, Calif., Oct. 08, 2024 – NKGen Biotech Inc. (Nasdaq: NKGN), a clinical-stage biotech firm, has announced upcoming poster presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference (CTAD) in Madrid, Spain, from October 29 to November 1, 2024. These presentations will focus on the final report of a Phase 1 dose escalation study and a preliminary report of the Phase 1 cohort in the follow-up Phase 1/2a study of their therapeutic candidate, troculeucel, in patients with Alzheimer’s disease.

The first presentation, titled "Treatment of Moderate Alzheimer’s Disease Subjects with Expanded Non-genetically Modified Natural Killer Cells (troculeucel; SNK01) with Enhanced Activity – Report of the Phase I results of the Phase I/IIa Study," will showcase findings from the initial phase of the study. The authors of this study include Paul Y. Song, Lucia Hui, Hank Lee, Juan Mata, Katia Betito, Harry Chung, and Jesse Carr. This poster will be part of the Clinical Trials: Results session and can be viewed from Tuesday, October 29, 2024, at 3:00 pm to Wednesday, October 30, 2024, at 5:00 pm CET.

The second presentation, "Use of Non-genetically Modified Natural Killer Cells (SNK01) With Enhanced Activity in Subjects with Active Alzheimer’s Disease. Further Biomarker Analysis and Implications for Use in Prevention," will delve into the further biomarker analysis and potential preventative applications of troculeucel. The contributing authors for this poster are Paul Song, Clemente Humberto Zúñiga Gil, Blanca Isaura Acosta Gallo, Cesar Alejandro Amescua, Rufino Menchaca Díaz, Sean Hong, Juan Mata, Katia Betito, Hank Lee, Yoonmi Kang, and Lucia Hui. This presentation is scheduled within the Clinical Trials: Biomarkers Including Plasma session and will also be accessible from October 29 to October 30 during the same hours.

Copies of these posters will be uploaded to the Scientific Publications page of NKGen Biotech’s website post-conference. Additionally, the full abstracts will be featured in a special CTAD edition of the Journal of Prevention of Alzheimer’s Disease (JPAD).

NKGen Biotech focuses on pioneering natural killer (NK) cell therapeutics, particularly troculeucel, an innovative cell-based drug candidate. Troculeucel is an ex vivo expanded autologous NK cell immunotherapy aimed at treating neurodegenerative disorders and various cancers. The World Health Organization (WHO) has designated "troculeucel" as the International Nonproprietary Name (INN) for SNK01, which signifies an important milestone in the drug's development and recognition.

NKGen Biotech, headquartered in Santa Ana, California, is dedicated to the development and commercialization of both autologous and allogeneic NK cell therapeutics, striving to advance treatments for a wide array of diseases.